Edition:
United States

OncoGenex Pharmaceuticals Inc (OGXI.OQ)

OGXI.OQ on NASDAQ Stock Exchange Capital Market

0.49USD
26 Sep 2016
Change (% chg)

$-0.02 (-3.05%)
Prev Close
$0.51
Open
$0.51
Day's High
$0.51
Day's Low
$0.49
Volume
6,178
Avg. Vol
44,675
52-wk High
$2.83
52-wk Low
$0.46

Select another date:

Tue, Aug 16 2016

OncoGenex seeks strategic alternatives after drug study fails

OncoGenex Pharmaceuticals Inc said it was exploring strategic alternatives after its experimental drug failed to show survival benefit in a late-stage study in patients with advanced prostate cancer.

UPDATE 1-OncoGenex seeks strategic alternatives after drug study fails

Aug 16 OncoGenex Pharmaceuticals Inc said it was exploring strategic alternatives after its experimental drug failed to show survival benefit in a late-stage study in patients with advanced prostate cancer.

BRIEF-Oncogenex's Phase 3 trial of Custirsen in men did not meet primary endpoint

* Oncogenex announces results from the phase 3 affinity trial of custirsen in men with metastatic castrate-resistant prostate cancer

BRIEF-Oncogenex Pharma Q2 revenue $2.1 million vs est $1.2 million

* Oncogenex pharmaceuticals, inc. Reports financial results for second quarter 2016

BRIEF-Oncogenex Pharmaceuticals qtrly loss per share $0.12

* Oncogenex pharmaceuticals, inc. Reports financial results for first quarter 2016

Select another date: